Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics

PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.

Who May Be Eligible (Plain English)

Who May Qualify: - Provision of willing to sign a consent form prior to any study-specific procedures. - Male or female aged at least 18 years. - ECOG PS - 0/1-2. Who Should NOT Join This Trial: - Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment. - Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures. * Male or female aged at least 18 years. * ECOG PS - 0/1-2. Exclusion Criteria: * Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment. * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

Treatments Being Tested

OTHER

blood, stool and tissue samples collection

blood, stool and tissue samples collection before and during the treatment, as applicable

Locations (1)

Baylor Scott and White Research Institute
Dallas, Texas, United States